Commercially available prognostic molecular models in early-stage lung cancer: a review of the Pervenio Lung RS and Myriad myPlan Lung Cancer tests

Abstract

Lung cancer is the most common cause of cancer death in the USA. Patients with early-stage non-small-cell lung cancer have a 5-year survival of approximately 70%. Effective, accurate and clinically relevant prognostic tests are needed to determine which patients are at high risk of disease-specific mortality after surgical resection. Currently, there are two commercially available prognostic tests based on differential gene expression for this purpose: the Myriad myPlan™ Lung Cancer and Pervenio™ Lung RS tests. One stratifies patients into two risk groups and the other into three risk groups. Both have been validated in independent patient cohorts and neither has yet been demonstrated to improve survival. These tests have the potential to risk-stratify which patients with early-stage lung cancer will have a higher likelihood of disease recurrence after surgical resection and may benefit from adjuvant treatment.

Keywords:

• gene expression profile
• lung cancer prognostic test
• myPlan™ Lung Cancer
• Pervenio™ Lung RS
• prognostic model

Financial & competing interests disclosure

The authors have received honoraria, research funding and travel reimbursements from Myriad Genetics, Inc. (Salt Lake City, UT, USA). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Key issues

• There are two molecular prognostic tests that measure expression levels of genes, which function in regulating cell growth and division to determine a risk category for 5-year lung cancer mortality.

• The Pervenio™ Lung RS test measures the expression profile of 14 genes in a specific tumor and stratifies the calculated risk score to a low-, intermediate- or high-risk category; the intermediate- and high-risk categories had a significantly higher risk of mortality as compared with the low-risk category.

• The Myriad myPlan™ Lung Cancer test measures the expression profile of 46 genes to calculate a CCP score; the CCP score and pathological stage are used to calculate a PS, with low PS versus high PS being significantly associated with different 5-year survival rates.

• These tests are undergoing cost and clinical utility evaluations and may prove beneficial in determining the need for adjuvant chemotherapy in early-stage lung adenocarcinoma.